7 March 2022 - Chugai files for regulatory approval following the results from the Phase 3 ELEVATE-TN trial evaluating Gazyva and acalabrutinib in patients with untreated chronic lymphocytic leukaemia.

Chugai Pharmaceutical and Nippon Shinyaku announced that Chugai filed a regulatory application with the Ministry of Health, Labour and Welfare, for approval of an anti-cancer agent/humanised anti-CD20 monoclonal antibody Gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukaemia.

Read Chugai Pharmaceutical press release